Phio Pharmaceuticals Corp represents innovation, commitment, and excellence in the field of biotechnology. The company's corporate philosophy revolves around advancing the development of RNA-based therapeutics to address unmet medical needs. Phio Pharmaceuticals Corp strives to improve patients' lives by harnessing the power of RNA interference, enabling targeted gene silencing and modulation. With a strong focus on research and development, the company seeks to revolutionize the treatment of various diseases, including cancer and inflammatory disorders. By constantly pushing boundaries and utilizing cutting-edge technologies, Phio Pharmaceuticals Corp aims to bring groundbreaking therapies to patients worldwide.

Phio Pharmaceuticals Corp primarily operates in the United States.

Phio Pharmaceuticals Corp, a distinguished biotechnology company, has successfully reached numerous significant milestones. Notably, Phio Pharmaceuticals Corp attained important accomplishments such as advancing its innovative RNAi technology platform and expanding its intellectual property portfolio. Moreover, the company has successfully completed preclinical studies, showcasing the potential of its RNA-based therapeutics in various therapeutic areas. Through strategic collaborations and partnerships, Phio Pharmaceuticals Corp has strengthened its position in the competitive biotech industry. With a strong focus on research and development, the company continues to make remarkable progress in advancing novel RNAi-based treatments, thereby fostering hope for improved healthcare outcomes.

Phio Pharmaceuticals Corp is a company with a rich history and promising future. Established in [insert year], Phio Pharmaceuticals Corp has emerged as a key player in the field of biotechnology. The company focuses on developing innovative RNA therapeutics to address unmet medical needs. With a team of dedicated scientists and researchers, Phio Pharmaceuticals Corp has achieved significant milestones in advancing RNA interference technology. Their cutting-edge research has paved the way for potential treatments in various disease areas, such as cancer, genetic disorders, and viral infections. As a leading biotech organization, Phio Pharmaceuticals Corp continues to strive for breakthroughs in the field of RNA therapeutics, holding great potential for medical advancements and improving patients' lives.

The main competitors of Phio Pharmaceuticals Corp in the market include notable pharmaceutical companies such as Novartis AG, Pfizer Inc., Johnson & Johnson, and Roche Holding AG.

Phio Pharmaceuticals Corp is primarily active in the biopharmaceutical industry.

The business model of Phio Pharmaceuticals Corp focuses on developing novel RNA therapeutics to treat various diseases. They specialize in harnessing the power of RNA interference (RNAi) and oligonucleotide-based therapeutics to selectively silence disease-causing genes. By targeting specific genes responsible for disease progression, Phio Pharmaceuticals aims to enhance the body's natural defense mechanisms and provide innovative treatment options for patients. With a strong emphasis on research and development, Phio Pharmaceuticals is committed to advancing its pipeline of RNA-based therapies to address unmet medical needs and improve patient outcomes.

P/E-talet för Phio Pharmaceuticals är −0,47.

Det Phio Pharmaceuticals KUV är 0,06.

AlleAktien Qualitätsscore för Phio Pharmaceuticals är 2/10.

förväntade Phio Pharmaceuticals omsättningen är 112,50 Mkr. USD.

förväntade Phio Pharmaceuticals vinst är −14,37 Mkr. USD.

The company Phio Pharmaceuticals Corp specializes in the development and commercialization of therapies for the treatment of cancer and chronic infections. Their business model is based on utilizing their own technology platforms to develop, patent, and market innovative therapies. Phio's main technology platform is called "Self-Delivering RNAi (sd-rxRNA)". This technology allows for targeted suppression of specific genes associated with diseases such as cancer and infections. It is based on the use of Ribonucleic acid (RNA) as a therapeutic agent, with Phio using a proprietary form of RNA that can penetrate cells and exert its effects without the need for additional transfection agents or vectors. In recent years, Phio has focused on developing therapies for rare and difficult-to-treat forms of cancer. They are currently working on several product candidates in various stages of clinical development, with their lead candidate being "PH-762", an sd-rxRNA therapy for pleural-pulmonary malignant mesothelioma (PPM), a rare form of lung cancer. Phio has already published promising Phase I clinical data for PH-762, demonstrating good tolerability and efficacy. Phio has also entered into an agreement with the National Institutes of Health (NIH) in the United States to further develop its technology platforms and products. The company aims to collaborate with the NIH and other partners to develop new therapies for viral and bacterial infections, as well as rare diseases. To enhance its technology platforms and accelerate product development, Phio has also made targeted acquisitions and licensing agreements in recent years. In 2018, they acquired RXi Pharmaceuticals to expand their sd-rxRNA technology platform. Additionally, Phio has entered into several strategic partnerships with other companies to gain access to new technology platforms and product candidates. Phio operates on a business-to-business (B2B) model, licensing or selling its products and technology platforms to other pharmaceutical and biotech companies. They have already established multiple partnerships and licensing agreements to market their sd-rxRNA technology platform and products. For example, Phio has partnered with Glycostem Therapeutics to utilize the sd-rxRNA technology platform for the production of product candidates for cancer immunotherapy. Overall, Phio's business model relies on utilizing its own technology platforms to develop innovative therapies for cancer and infections. The company focuses on developing therapies for rare forms of cancer and has already published Phase I clinical data for their lead product candidate. Phio has also formed several partnerships to gain access to new technology platforms and product candidates, and operates on a B2B model, licensing or selling their products and technology platforms to other companies.

Phio Pharmaceuticals delar ut en utdelning på 0 USD fördelad över utbetalningar per år.

Utbytet kan för närvarande inte beräknas för Phio Pharmaceuticals eller så distribuerar bolaget inget utbyte.

ISIN för Phio Pharmaceuticals är US71880W3034.

WKN för Phio Pharmaceuticals är A2PYB0.

Ticker-symbolen för Phio Pharmaceuticals är PHIO.

Under de senaste 12 månaderna betalade Phio Pharmaceuticals en utdelning på . Detta motsvarar en direktavkastning på ungefär . För de kommande 12 månaderna förväntas Phio Pharmaceuticals betala en utdelning på 0 USD.

Aktiens direktavkastning för Phio Pharmaceuticals är för närvarande .

Phio Pharmaceuticals betalar ut dividenden kvartalsvis. Denna distribueras under månaderna .

Phio Pharmaceuticals betalade utdelning varje år under de senaste 0 åren.

För de kommande 12 månaderna förväntas utdelningar uppgå till 0 USD. Detta motsvarar en utdelningsavkastning på 0 %.

Phio Pharmaceuticals tilldelas sektorn 'Hälsa'.

För att få den senaste utdelningen från Phio Pharmaceuticals den 2024-11-06 på 0 USD var du tvungen att ha aktien i ditt depå innan ex-dagen den 2024-11-06.

Utdelningen av den senaste dividenden skedde den 2024-11-06.

Under år 2023 delade Phio Pharmaceuticals ut 0 USD i form av utdelningar.

Utdelningarna från Phio Pharmaceuticals betalas ut i USD.